Rahul Tendulkar, MD

Burnout & moral injury in medicine have affected so many health care workers. As a mid-career physician, here’s what I’ve learned to combat it - I hope others find it to be helpful. In Search of Joy and Meaning in Modern Medicine @JCOOP_ASCO ascopubs.org/doi/pdf/10.120…

@jessica_bai_ @S_W_R_O @PennRadOnc Congratulations!!!

I am absolutely ecstatic to share that I’ll be going back home to Philly for my prelim year and radiation oncology residency at Penn!! So grateful for all the unwavering support from my family, mentors, and peers. #match2026 #radonc @PennRadOnc @S_W_R_O

@kendallngarrett @UCSDRadMed @CWRUSOM Congratulations!!!

Overjoyed to announce I matched at @UCSDRadMed for radiation oncology! I am so excited, and so grateful to all of the residents and attendings who supported and mentored me throughout this journey! I’m going home! ☀️☢️ #match2026

Cleveland Clinic Rad Onc is thrilled to match these 3️⃣ superstars!!!! 🌟

We are off at #2026RSS, with @BenSlotman opening address. Fantastic opening talks from @ErinMurphyMD and Dr Dwight Heron on stereotactic re-irradiation! Lots of learning to do for primary CNS and #hnscc head and neck! #radonc @the_RSS.

🚀 Largest prospective SABR cohort in inoperable RCC. Pooled FASTRACK trials show 98% local control at 5 years, excellent CSS, low ≥G3 toxicity and no late safety signals. A durable, non‑invasive, kidney‑sparing option—now poised for randomized comparison vs surgery. #EAU26

A must-read review on KRAS inhibitors! 🔗doi.org/10.1016/j.ccel… @Cancer_Cell @OncoAlert

#EAU26 Plenary Evidence from RCTs for MDT for oligorecurrent HSPC @urotoday

#EAU26 long-term results from randomized ARTO Ph II trial (SBRT + AA vs AA): • bPFS: 43 vs 17 mo (HR 0.49, p<0.001) • rPFS: 44 vs 17 mo (HR 0.48, p<0.001) • OS: NR vs 50 mo (HR 0.55, p=0.02) • PCSS: NR vs NR (HR 0.37, p=0.006) Supports Ph 3 trials of met-directed SBRT + systemic Rx in oligomet CRPC @urotoday

We have never run a sham-controlled RCT for total knee replacement. Not once. The most commonly performed orthopedic procedure in the United States, 700,000+ per year, has never been tested against placebo. And yet when low-dose radiotherapy (LDRT) for knee OA is presented, the first objection is always: "Where's the sham-controlled data?" That double standard is worth naming out loud. Here is what LDRT actually has: → 2 positive sham controlled trials (Korean and Iranian) → A 292-patient prospective RCT (Russian) with 11 year follow-up → 4.5x difference in pain scores at 36 months across every domain (pain, stiffness, function, quality of life) → Plain-film radiography and MRI at 10 years showing a statistically significant reduction in marked progression → A 50-year European safety record with no meaningful toxicity Here is what the treatments currently in OA guidelines have: → NSAIDs: known cardiovascular, renal, and GI harm at chronic doses → Glucosamine/chondroitin: failed large RCTs. Still in some guidelines. → Corticosteroid injections: emerging evidence of accelerated cartilage loss with repeat use → TKA: no sham trial. Ever. If LDRT was a pill, it would be in every guideline. The evidence bar being applied to LDRT is not being applied to anything else in this space. The critics aren't wrong that we need a multicenter sham-controlled trial. We do. That's the ask. But the argument that the current evidence is insufficient to justify treatment while we continue recommending interventions with weaker or more harmful evidence bases is not scientific rigor. It is asymmetric scrutiny. The field has been waiting decades for a non-surgical, disease-modifying treatment for OA. The data suggests we may have had it all along. That conversation is overdue.

Advances in the planning and delivery of radiation treatments have come from efforts to simultaneously reduce negative effects in normal tissues and enhance tumor control (seen in figure). Learn more: nejm.org/doi/full/10.10…

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T

@d_golden @IJROBP @sueyom Dan, thank you for sharing your story so openly. You are an inspiration and will help so many people.

Thanks to @IJROBP & @sueyom for allowing me to share my #mentalhealth journey, "After #Burnout: Reigniting the Flame." I hope this essay can help others out there in medicine that might be struggling. sciencedirect.com/science/articl… #physicianburnout #anxiety #depression #wellness

Medicine teaches you: Competence matters more than noise. Consistency beats brilliance. Kindness beats credentials. And humility is the only degree that never expires.

It’s 75° and sunny in Florida today! Come thaw out with us at the @ClevelandClinic 18th Annual International Symposium on SBRT & SRS and @IntRRF International Radiosurgery Research Foundation Meeting! More info here: ccfcme.org/SBRT

One of my favorite classic threads here on academic twitter 👇

kindness toward beginners when you are an expert is a sign of good character

The first modern review on the treatment of tendinopathies with low-dose radiotherapy (LDRT) has now been published and is available online. This work represents a truly international collaboration, bringing together expertise from across disciplines and continents. Congratulations to all of the authors involved in producing this timely and much-needed review. Special appreciation to Dr. Alexander Rühle for the invitation and leadership in advancing this important area of functional radiotherapy. Link: kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…